Liquid chromatographic method for determination of moxifloxacin and dexamethasone sodium phosphate in eye drops

Katakam Prakash\textsuperscript{a} and Karanam R. Sireesha\textsuperscript{b}\textsuperscript{*}

\textsuperscript{a} Nirmala College of Pharmacy, Mangalagiri, Guntur-522510, Andhra Pradesh, India.
\textsuperscript{b} S.N. Vanita Pharmacy Mahavidyalaya, Exhibition grounds, Hyderabad-500001, Andhra Pradesh, India.

\textbf{Received:} 13/06/2011; \textbf{Accepted:} 20/11/2011

\textbf{Abstract}

A liquid chromatographic method was developed and validated for the simultaneous determination of moxifloxacin and dexamethasone sodium phosphate in bulk and pharmaceutical formulations. Optimum separation was achieved in less than 5 min using a C18 column (250 mm x 4.6 mm i.d., 5µ particle size) by isocratic elution. The mobile phase consisting of a mixture of 0.01 M phosphate buffer (pH 6.0) and acetonitrile (50:50, v/v) was used. Column effluents were monitored at 254 nm at a flow rate of 1 mL min\textsuperscript{-1}. Retention times of moxifloxacin and dexamethasone sodium phosphate were 2.58 and 3.95 min respectively. The linearity of moxifloxacin and dexamethasone sodium phosphate was in the range of 10-60 µg mL\textsuperscript{-1} and 2-12 µg mL\textsuperscript{-1} respectively. Developed method was economical in terms of the time taken and amount of solvent consumed for each analysis. The method was validated and successfully applied to the simultaneous determination of moxifloxacin and dexamethasone sodium phosphate in bulk and pharmaceutical formulations.

\textbf{Keywords:}
Simultaneous determination; HPLC; isocratic elution; validation

1. Introduction

Dexamethasone sodium phosphate (DSP) is a highly selective glucocorticoid which is widely used in ocular inflammatory diseases. Its chemical name is 9- fluoro-11b, 17, 21-trihydroxy-16α- methylpregna-1, 4- diene-3, 20-dione 21-(dihydrogen phosphate) disodium salt [1]. Moxifloxacin (MFN) is a fourth generation fluoroquinolone antibiotic used in bacterial infections. It is chemically 1-cyclopentyl-7-[(1S, 6S)-2, 8-diazabicyclo (4.3.0) non-8-yl]-6-fluoro-8-methoxy-4-oxo-3-quinoline carboxylic acid. Dexamethasone in combination with moxifloxacin is used in several anti-infective eye preparations to treat acute and sub acute conjunctivitis [2] caused by susceptible strains of the following aerobic gram positive and negative bacteria such as \textit{S. aureus, S. epidermidis, S. pneumonia} and \textit{H. influenza}. In the literature, there are methods described for the determination of fluoroquinolones and dexamethasone in aqueous samples [3-6] and biological fluids [7-13] by liquid chromatography (LC), liquid chromatography-fluorescence detection (LC-FD) and High performance thin layer chromatography (HPTLC). A few methods have also been described for the simultaneous determination of Dexamethasone and fluoroquinolones with other drugs such as Chloremphenicol and Prednisolone [14-16]. But simultaneous determination of MFN

\textsuperscript{*}Corresponding Author
E-mail: rupakr1@rediffmail.com; pkatakam9@rediffmail.com
ISSN: 1306-3057, Moment Publication ©2012
and DSP has not been reported earlier in the literature. So an attempt was made to develop a HPLC method for the estimation of these drugs available as eye drops.

The purpose of the present study was to develop a simple, sensitive, precise and accurate HPLC method for simultaneous determination of MFN and DSP in bulk and pharmaceutical formulations. The developed method has been validated [17, 18] by evaluation of the system suitability, specificity, linearity, limit of detection and quantification, precision, accuracy and recovery. The validated method was applied to the commercially available pharmaceutical formulations containing both the drugs.

2. Experimental

2.1. Materials

DSP and MFN were obtained as gift samples from Ajanta pharmaceuticals Ltd, Mumbai. HPLC grade acetonitrile was purchased from SD fine chemicals, India. Triple distilled water was used during the study. The pharmaceutical formulations containing 5 mg mL⁻¹ of MFN and 1 mg mL⁻¹ DSP (MILFLOX-DM eye drops, united technologies Ltd, India.) was purchased from local market.

2.2. Instrumentation

A high performance liquid chromatograph (Shimadzu-10 AT VP) equipped with two pumps (Model-10AT VP) and Shimadzu UV-Visible detector (SPD-10AT VP), ultrasonic bath (Spincotech Pvt. Ltd, India).

2.3. Chromatographic conditions

For chromatographic analysis, a Hypersil BDS C18 column (250 mmx4.6 mm i.d, 5μ particle size) was used. Separation was carried out by isocratic elution. The mobile phase consisting of a mixture of 0.01 mol L⁻¹ phosphate buffer (pH 6.0) and acetonitrile (ACN) in the ratio of 50:50, v/v was used. Mobile phase was filtered under vacuum from 0.45 membrane filter and degassed in ultrasonic bath for 30 min before passing through the instrument. The injection volume was 20 μL and the flow rate was 1 mL min⁻¹. UV detection was carried out at 254 nm. Chromatographic separations were carried out at room temperature (25-30°C).

2.4. Preparation of standard solution

Stock standard solutions of MFN and DSP were prepared in the mobile phase at a concentration of 1000 μg mL⁻¹ and 200 mg mL⁻¹. Working standard solutions was prepared by serial dilution of stock solutions with the mobile phase.

2.5. Sample preparation

Sample solutions of MFN and DSP were prepared at a concentration of 1000 mg mL⁻¹ and 200 mg mL⁻¹ by diluting 5 mL of the ophthalmic solution to 25 ml with the mobile phase. From this 0.4 mL was taken and diluted to 10 mL to get a concentration of 40 mg mL⁻¹ and 8 mg mL⁻¹ of MFN and DSP.

2.6. Method Validation

The developed analytical method was validated as per ICH and USP guidelines for the parameters like linearity, limit of detection (LOD), limit of quantification (LOQ), precision, specificity, accuracy, robustness, and system suitability.
2.6.1. Linearity

Six working standard solutions of each analyte in the concentration range of 10-60 µg mL\(^{-1}\) for MFN and 2-12 µg mL\(^{-1}\) for DSP were prepared in triplicate and injected. Calibration curves were constructed by plotting concentration versus mean peak area.

2.6.2. Limits of detection and Quantification

According to ICH, limit of detection (LOD) is the lowest concentration of the analyte that can be detected and limit of quantification (LOQ) is the lowest concentration of analyte that can be detected with acceptable accuracy and precision. LOD and LOQ are calculated from the formulae 3.3 \(\frac{\sigma}{s}\) and 10 \(\frac{\sigma}{s}\) respectively. Where \(\sigma\) is the standard deviation of y-intercepts of the regression line and s is the slope of the calibration curve.

2.6.3. Precision

The precision of the method was evaluated in terms of intermediate precision i.e., intra-day and inter-day precision and precision by different analysts. For intra-day precision three different concentrations of MFN and DSP in the linearity range was prepared in triplicate and was analyzed during the same day. For inter-day precision the same concentrations were analyzed on three consecutive days and RSD values were calculated. Instrument precision was analyzed by injection repeatability. This was examined by analyzing six injections of the mixture containing 40 and 8 µg mL\(^{-1}\) of MFN and DSP, respectively. RSD values were calculated from the peak areas and retention times of MFN and DSP.

2.6.4. Accuracy

Accuracy of the method was determined by recovery studies. These studies were carried out by addition of known amounts of MFN and DSP to a sample solution of known concentration and comparing calculated and measured concentrations. A sample solution containing MFN and DSP (1 and 0.2 mg mL\(^{-1}\), respectively) was prepared by diluting 5 mL of the ophthalmic solution to 25 mL in a volumetric flask, and make up the solution with the mobile phase. Samples (0.3 mL) of the filtered solution were transferred to 10 mL volumetric flasks containing 0.15, 0.25, and 0.35 mL of MFN and DSP standard solution and analyzed.

2.6.5. Specificity

Specificity of an analytical method may be defined as the ability of the method to measure accurately and specifically the analyte in presence of additional components such as matrix, impurities, degradation products and other related substances. The chief excipient present in the eye drops is benzalkonium chloride which is used as preservative. Sample solution containing benzalkonium chloride was injected into the system and chromatogram was recorded.

2.6.7. Robustness

Robustness of the method was evaluated by deliberately varying method parameters such as detection wavelength and flow rate. Detection wavelength was changed from 254 nm to 254±2 nm and flow rate was changed from 1 mL min\(^{-1}\) to 1±0.1 mL min\(^{-1}\). Effect of these changed parameters was studied by injecting the sample in to the system.

2.6.8. System Suitability

System suitability was established in order to determine the adequate resolution and reproducibility of the proposed method. Suitability parameters including retention factor, resolution, asymmetry factor, plate number were investigated.
2.7. Assay of the marketed formulation

The developed method was applied to the simultaneous determination of MFN and DSP in pharmaceutical formulations. Sample was analyzed by performing six independent determinations and each series was injected in triplicate.

3. Results and discussion

3.1. Mobile phase optimization

Chromatographic parameters were optimized to develop a HPLC method for simultaneous determination of MFN and DSP with short analysis time (<5 min), and acceptable resolution (RS>2). Various compositions of mobile phases like methanol: buffer and ACN: buffer in different ratios were tried. But with 0.01 mol L\(^{-1}\) phosphate buffer (pH 6.0) and ACN in the ratio of 50:50 at a flow rate of 1 mL min\(^{-1}\), symmetrical peaks with good resolution were obtained. The optimum wavelength for detection was set at 254 nm at which better detector response for both drugs was obtained. The retention times were 2.58 and 3.95 min for MFN and DSP respectively (Fig. 1).

![Typical chromatogram for the standard solution of MFN and DSP](image)

**Fig. 1.** Typical chromatogram for the standard solution of MFN and DSP

3.2. Validation

Calibration graphs were constructed by plotting the peak area versus their corresponding concentrations. Good linearity was obtained in the range of 10-60 µg mL\(^{-1}\) and 2-12 µg mL\(^{-1}\) for MFN and DSP. The results are shown in Table 1. Limit of detection (LOD) and limit of quantification (LOQ) were calculated from the slope and standard deviation of y-intercepts of the regression line of the calibration curve. For MFN it was found to be 0.075 and 0.228 µg mL\(^{-1}\) and for DSP 0.028 and 0.086 µg mL\(^{-1}\) respectively. The precision of the method and instrument precision was evaluated and relative standard deviation (RSD) values were calculated. The RSD values for MFN and DSP showed that the precision of the method was satisfactory. The results are shown in Table 2. The accuracy of the method was determined by recovery studies. The recoveries were close to 100% for MFN and DSP; the results are given in the Table 3. Developed method was found to be robust when the detection
wavelength and flow rate was changed from 254 nm to 254±2 nm and 1 mL min⁻¹ to 1±0.1 mL min⁻¹. There was no considerable change in the peak areas and retention times. Using 0.9 mL min⁻¹ flow rate, the retention time for MFN and DSP were found to be 2.89 and 4.4 min respectively and with 1.1 mL min⁻¹ flow rate, retention times for MFN and DSP were found to be 2.38 and 3.63 min, respectively without affecting the resolution of the drugs. When detection wavelength was changed to 254±2 nm, the retention time for MFN and DSP were not changed from the normal. System suitability parameters are shown in Table 4.

Table 1. Linearity by regression analysis (n=6)

<table>
<thead>
<tr>
<th>Substance</th>
<th>R²</th>
<th>Slope</th>
<th>Conc. Range (µg mL⁻¹)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MFN</td>
<td>0.999</td>
<td>14.44</td>
<td>10-60</td>
</tr>
<tr>
<td>DSP</td>
<td>0.999</td>
<td>24.56</td>
<td>2-12</td>
</tr>
</tbody>
</table>

Table 2. Precision expressed as %RSD

<table>
<thead>
<tr>
<th>Parameters</th>
<th>MFN</th>
<th>DSP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intra-day precision (n=3)</td>
<td>0.698</td>
<td>0.746</td>
</tr>
<tr>
<td>Inter-day precision (n=3)</td>
<td>1.73</td>
<td>1.33</td>
</tr>
<tr>
<td>Analyst precision (n=6)</td>
<td>0.08</td>
<td>0.19</td>
</tr>
<tr>
<td>Injection repeatability for tR (n=6)</td>
<td>0.0</td>
<td>0.13</td>
</tr>
<tr>
<td>Injection repeatability for peak area</td>
<td>0.24</td>
<td>0.32</td>
</tr>
<tr>
<td>Asymmetry factor</td>
<td>2.02</td>
<td>1.48</td>
</tr>
</tbody>
</table>

Table 3. Recovery studies (n=6)

<table>
<thead>
<tr>
<th>Drug</th>
<th>Concentration (µg mL⁻¹)</th>
<th>Amount recovered (µg mL⁻¹)</th>
<th>Recovery, %</th>
<th>%RSD</th>
</tr>
</thead>
<tbody>
<tr>
<td>MFN</td>
<td>45</td>
<td>44.6</td>
<td>99.13</td>
<td>0.85</td>
</tr>
<tr>
<td></td>
<td>55</td>
<td>54.65</td>
<td>99.37</td>
<td>0.33</td>
</tr>
<tr>
<td></td>
<td>65</td>
<td>64.36</td>
<td>99.03</td>
<td>0.06</td>
</tr>
<tr>
<td>DSP</td>
<td>9</td>
<td>8.97</td>
<td>99.68</td>
<td>0.39</td>
</tr>
<tr>
<td></td>
<td>11</td>
<td>10.94</td>
<td>99.53</td>
<td>1.62</td>
</tr>
<tr>
<td></td>
<td>13</td>
<td>12.9</td>
<td>99.3</td>
<td>0.7</td>
</tr>
</tbody>
</table>

‘n’ is number of determinations and RSD is relative standard deviation

Table 4. System suitability parameters (n=6)

<table>
<thead>
<tr>
<th>Parameters</th>
<th>MFN</th>
<th>DSP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Retention time (tR)</td>
<td>2.58</td>
<td>3.95</td>
</tr>
<tr>
<td>Asymmetry factor</td>
<td>1.7</td>
<td>1.5</td>
</tr>
<tr>
<td>Resolution</td>
<td>-</td>
<td>7.2</td>
</tr>
<tr>
<td>Number of plates</td>
<td>3266</td>
<td>6718</td>
</tr>
</tbody>
</table>

‘n’ is number of determinations

3.3. Assay of the marketed formulation

According to ICH in the case of assay, demonstration of specificity requires that the procedure is unaffected by the presence of impurities or excipients. The assay value of the marketed formulation was found to be within the limits. The low RSD value indicated
suitability of this method for routine analysis of MFN and DSP in pharmaceutical dosage forms. Chromatogram of the sample shows that there was no interference from the excipients present in the formulation; this indicates the specificity of the method (Fig. 2). The results are shown in Table 5.

**Table 5.** Assay of eye drops (n=6)

<table>
<thead>
<tr>
<th>Drug</th>
<th>Label claim (mg mL⁻¹)</th>
<th>Amt found (mg mL⁻¹)</th>
<th>Mean Recovery, %</th>
<th>%RSD</th>
</tr>
</thead>
<tbody>
<tr>
<td>MFN</td>
<td>5</td>
<td>5</td>
<td>99.82</td>
<td>0.38</td>
</tr>
<tr>
<td>DSP</td>
<td>1</td>
<td>1</td>
<td>99.58</td>
<td>0.53</td>
</tr>
</tbody>
</table>

MILFLOX-DM eye drops containing 5 mg mL⁻¹ MFN and 1 mg mL⁻¹ DSP

**Fig. 2.** Chromatogram for the sample solution of MFN and DSP

**Acknowledgements**

Authors thank Ajanta Pharma Ltd, Mumbai, India for providing gift samples of MFN and DSP.

**References**


